Seres Therapeutics Inc (MCRB)

$17.85 +0.12 (0.68%)
Market Cap 155.22M
Revenue (ttm) 0.00
Net Income (ttm) 140,000.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 65,900
Avg Vol 170,084
Day's Range N/A - N/A
Shares Out 8.76M
Stochastic %K 10%
Beta 0.19
Analysts Sell
Price Target $16.00

Company Profile

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline pr...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 945 9626
Address:
101 Cambridgepark Drive, Cambridge, United States
Kaniel1
Kaniel1 Oct. 25 at 12:04 PM
$MCRB In the next few days something has to happen we’re at the final stage and major things have been done let’s see what happens
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 11:19 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $MCRB Current Share Price: $17.85 Contracts: $MCRB January 15, 2027 $20 Calls Scale in: $5.00- $6.11 Scale out: $7.77-$9.99 Can Easily Capture: 60% ROI Blended DTE: 447 Days | Join Elites here: https://liquidtheta.com
0 · Reply
Bullbullthara
Bullbullthara Oct. 25 at 3:42 AM
$MCRB Did anyone found any details about seres presentation about post HOC data from ser 155 1b in IDWeek on oct 20th ..? I couldnt find anything ...
1 · Reply
jamstah
jamstah Oct. 24 at 8:46 PM
$MCRB 60k shares less in short interest
0 · Reply
Rawbinhood
Rawbinhood Oct. 24 at 8:09 PM
$MCRB They are return shares that were short!!!
0 · Reply
BioCrazy1
BioCrazy1 Oct. 24 at 6:56 PM
$MCRB yesterday's volume was 50K. I don't think we do that today, currently at 30K.
0 · Reply
Kenny1207
Kenny1207 Oct. 24 at 6:20 PM
$MCRB A week to forget. 5 and half % doen on very low volume each of these days. I seriously hope we get some news next week. Its either Partnership or BO the wait is agonizing.
0 · Reply
coreholder
coreholder Oct. 24 at 5:46 PM
$MCRB Is November earnings here yet?
0 · Reply
BioCrazy1
BioCrazy1 Oct. 24 at 2:11 PM
$MCRB
0 · Reply
BioCrazy1
BioCrazy1 Oct. 24 at 2:02 PM
$MCRB Covering with no volume? It's not possible. This stock is a goat fck!
1 · Reply
Latest News on MCRB
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Oct 14, 2025, 7:00 AM EDT - 11 days ago

Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

Sep 23, 2025, 7:00 AM EDT - 4 weeks ago

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

More companies adopt co-CEO structure

Sep 22, 2025, 12:10 PM EDT - 4 weeks ago

More companies adopt co-CEO structure

IREN KKR LEN NFLX ORCL SBET

Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 7:00 AM EDT - 2 months ago

Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 9:47 PM EDT - 2 months ago

Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 6, 2025, 7:00 AM EDT - 2 months ago

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

SANA

Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough

Jul 29, 2025, 2:09 PM EDT - 3 months ago

Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

Jul 22, 2025, 7:01 AM EDT - 3 months ago

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

Seres Therapeutics Announces Leadership Transition

Jul 22, 2025, 7:00 AM EDT - 3 months ago

Seres Therapeutics Announces Leadership Transition

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

May 27, 2025, 7:00 AM EDT - 5 months ago

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript

May 7, 2025, 2:18 PM EDT - 6 months ago

Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 7, 2025, 7:00 AM EDT - 6 months ago

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

Apr 29, 2025, 7:00 AM EDT - 6 months ago

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

Apr 23, 2025, 7:00 AM EDT - 6 months ago

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

Seres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 11:04 AM EDT - 8 months ago

Seres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call Transcript

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 13, 2025, 7:00 AM EDT - 8 months ago

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025

Mar 4, 2025, 7:00 AM EST - 8 months ago

Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

Mar 3, 2025, 7:00 AM EST - 8 months ago

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

Jan 16, 2025, 7:00 AM EST - 10 months ago

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

Jan 9, 2025, 7:00 AM EST - 10 months ago

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

Dec 16, 2024, 7:00 AM EST - 11 months ago

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

Nov 22, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 10:28 AM EST - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

Sep 30, 2024, 5:15 PM EDT - 1 year ago

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé

Sep 27, 2024, 3:26 PM EDT - 1 year ago

Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

Sep 26, 2024, 4:01 PM EDT - 1 year ago

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Sep 23, 2024, 12:14 AM EDT - 1 year ago

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Sep 12, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 3:35 PM EDT - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript

Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024

Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 7, 2024, 4:00 PM EDT - 1 year ago

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023

Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science

Jun 6, 2024, 6:30 AM EDT - 1 year ago

Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science

Seres Therapeutics, Inc. (MCRB) Q1 2024 Earnings Call Transcript

May 11, 2024, 5:34 PM EDT - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q1 2024 Earnings Call Transcript

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 8, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024

May 6, 2024, 9:30 AM EDT - 1 year ago

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Apr 9, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

VKTX, JANX and these biotech stocks are surging in 2024

Apr 2, 2024, 2:10 AM EDT - 1 year ago

VKTX, JANX and these biotech stocks are surging in 2024

ARQT JANX VKTX AMLX RAPT RVNC

Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 3:33 PM EST - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Mar 5, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024

Feb 28, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024

Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference

Feb 27, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference

Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz

Feb 26, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

Jan 9, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Jan 4, 2024, 4:00 PM EST - 1 year ago

Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023

Dec 7, 2023, 7:46 PM EST - 2 years ago

Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023

Kaniel1
Kaniel1 Oct. 25 at 12:04 PM
$MCRB In the next few days something has to happen we’re at the final stage and major things have been done let’s see what happens
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 11:19 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $MCRB Current Share Price: $17.85 Contracts: $MCRB January 15, 2027 $20 Calls Scale in: $5.00- $6.11 Scale out: $7.77-$9.99 Can Easily Capture: 60% ROI Blended DTE: 447 Days | Join Elites here: https://liquidtheta.com
0 · Reply
Bullbullthara
Bullbullthara Oct. 25 at 3:42 AM
$MCRB Did anyone found any details about seres presentation about post HOC data from ser 155 1b in IDWeek on oct 20th ..? I couldnt find anything ...
1 · Reply
jamstah
jamstah Oct. 24 at 8:46 PM
$MCRB 60k shares less in short interest
0 · Reply
Rawbinhood
Rawbinhood Oct. 24 at 8:09 PM
$MCRB They are return shares that were short!!!
0 · Reply
BioCrazy1
BioCrazy1 Oct. 24 at 6:56 PM
$MCRB yesterday's volume was 50K. I don't think we do that today, currently at 30K.
0 · Reply
Kenny1207
Kenny1207 Oct. 24 at 6:20 PM
$MCRB A week to forget. 5 and half % doen on very low volume each of these days. I seriously hope we get some news next week. Its either Partnership or BO the wait is agonizing.
0 · Reply
coreholder
coreholder Oct. 24 at 5:46 PM
$MCRB Is November earnings here yet?
0 · Reply
BioCrazy1
BioCrazy1 Oct. 24 at 2:11 PM
$MCRB
0 · Reply
BioCrazy1
BioCrazy1 Oct. 24 at 2:02 PM
$MCRB Covering with no volume? It's not possible. This stock is a goat fck!
1 · Reply
BioCrazy1
BioCrazy1 Oct. 24 at 1:47 PM
$MCRB
0 · Reply
jamstah
jamstah Oct. 24 at 1:39 PM
$MCRB 150k shares
0 · Reply
HTNY
HTNY Oct. 24 at 10:57 AM
$MCRB $TSSI $ZETA $PGY $ANRGF My favorite criteria list this one. Home to the unloved and misunderstood. Fintech and Alts have been delicious this year
0 · Reply
BIOhmygod
BIOhmygod Oct. 24 at 9:28 AM
$MCRB the day is
0 · Reply
AsherLev
AsherLev Oct. 24 at 1:48 AM
$MCRB only way this thing is going up is with a takeover…
0 · Reply
BioCrazy1
BioCrazy1 Oct. 23 at 11:20 PM
$MCRB Borrow rate jumped up.
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 23 at 8:58 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $MCRB Current Share Price: $18.10 Contracts: $MCRB January 15, 2027 $20 Calls Scale in: $5.00- $6.11 Scale out: $7.77-$9.99 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
calbucs
calbucs Oct. 23 at 8:20 PM
$MCRB With over 8M shares outstanding . We need some volume to get this moving north , 50.6k Volume today . Very slow and only a few shorts playing the game right now . Wish they would get BO already and stop the misery .
0 · Reply
BioCrazy1
BioCrazy1 Oct. 23 at 5:42 PM
$MCRB Pathetic
0 · Reply
LionNoRichy
LionNoRichy Oct. 23 at 5:15 PM
$MCRB low volume but all's green but this...
0 · Reply
BioCrazy1
BioCrazy1 Oct. 23 at 5:08 PM
$MCRB Less than 20k shares traded with 3 hours to go.
1 · Reply
BioCrazy1
BioCrazy1 Oct. 23 at 2:05 PM
$MCRB Another blistering volume day so far 🙃.
2 · Reply